全基因组测序在精神分裂症及其他精神病性障碍中的诊断获益
该研究对251个家系(先证者含精神分裂症190例、分裂情感性障碍49例、其他伴精神病性症状情况48例)行临床全基因组测序(WGS)分析,诊断率为6.4%;发现精神分裂症候选基因集中罕见功能缺失变异显著富集,患者组精神分裂症多基因风险评分(PRS)较未患病亲属显著升高,并可为多数参与者提供CYP2D6药物基因组信息。作者认为WGS可能在研究与遗传咨询中发挥作用。
要点
- 251个家系中临床WGS诊断率为6.4%,检出SNV/小indel 14例(5.6%)、CNV 2例(0.8%)。
- 患者组在精神分裂症顶级候选基因集中罕见功能缺失变异较人群对照(N=6,840)显著富集。
- 患者组精神分裂症PRS较其未患病亲属显著升高。
核心结论
- 作者认为,WGS可能在精神分裂症及其他精神病性障碍个体及其家庭的研究与遗传咨询中发挥作用。
研究设计与样本
- 研究纳入以色列和美国的251个家系,先证者诊断为精神分裂症(N=190)、分裂情感性障碍(N=49)或其他伴精神病性症状的情况(N=48),主要涉及犹太、阿拉伯及其他欧洲血统。
- 228个家系(90.8%)行三联体(父母与先证者)WGS,其余家系WGS纳入父母及至少两名患病同胞。
- 次要分析评估特定基因集中罕见变异富集,并计算精神分裂症PRS。
主要发现
- 主要结局诊断率为6.4%;14例先证者(5.6%)检出临床显著的单核苷酸变异(SNV)或小插入缺失(indel),2例(0.8%)检出拷贝数变异(CNV)。
- 患者组在精神分裂症顶级候选基因集中罕见功能缺失变异较人群对照(N=6,840)显著富集。
- 患者组精神分裂症PRS较其未患病亲属显著升高。
- 基于CYP2D6基因型数据,可为大多数参与者提供药物基因组信息并确定其抗精神病药代谢者状态。
关键数值与推荐
- 主要结局诊断率为6.4%;SNV或小indel检出14例(5.6%),CNV检出2例(0.8%)。
- 患者组精神分裂症顶级候选基因集中罕见功能缺失变异较人群对照(N=6,840)显著富集。
- 患者组精神分裂症PRS较其未患病亲属显著升高。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Schizophrenia has a multifactorial etiology, involving a polygenic architecture. The potential benefit of whole genome sequencing (WGS) in schizophrenia and other psychotic disorders is not well studied. We investigated the yield of clinical WGS analysis in 251 families with a proband diagnosed with schizophrenia (N = 190), schizoaffective disorder (N = 49), or other conditions involving psychosis (N = 48). Participants were recruited in Israel and USA, mainly of Jewish, Arab, and other European ancestries. Trio (parents and proband) WGS was performed for 228 families (90.8%); in the other families, WGS included parents and at least two affected siblings. In the secondary analyses, we evaluated the contribution of rare variant enrichment in particular gene sets, and calculated polygenic risk score (PRS) for schizophrenia. For the primary outcome, diagnostic rate was 6.4%; we found clinically significant, single nucleotide variants (SNVs) or small insertions or deletions (indels) in 14 probands (5.6%), and copy number variants (CNVs) in 2 (0.8%). Significant enrichment of rare loss-of-function variants was observed in a gene set of top schizophrenia candidate genes in affected individuals, compared with population controls (N = 6,840). The PRS for schizophrenia was significantly increased in the affected individuals group, compared to their unaffected relatives. Last, we were also able to provide pharmacogenomics information based on CYP2D6 genotype data for most participants, and determine their antipsychotic metabolizer status. In conclusion, our findings suggest that WGS may have a role in the setting of both research and genetic counseling for individuals with schizophrenia and other psychotic disorders and their families.
引用
- Alkelai A, Greenbaum L, Docherty AR, et al. The benefit of diagnostic whole genome sequencing in schizophrenia and other psychotic disorders. Mol Psychiatry. 2021. PMID: 34799694. doi:10.1038/s41380-021-01383-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。